Gatiatulinaa, E.R.,
Popova, E.V.,
Polyakova, V.S.,
Skalnaya, A.A.,
Agletdinovd, E.F.,
Nikonorovae, A.A.,
Skalnyefgh, A.V.,
Tinkov, A.A. (2017) The primary objective of the
study was to assess the level of metals and trace elements in liver
Zelinska, N.,
Iotova, V.,
Skorodok, J.,
Malievsky, O.,
Peterkova, V.,
Samsonova, L.,
Rosenfeld, Ron G.,
Zadik, Zvi,
Jaron-Mendelson, Michal,
Koren, Ronit,
Amitzi, Leanne,
Raduk, Dmitri,
Hershkovitz, Oren,
Hart, Gili (2017) and children. The present trial was a safety and
dose-finding
study for weekly MOD-4023 in GHD children.
Design
Chatelain, Pierre,
Malievskiy, Oleg,
Radziuk, Klaudziya,
Senatorova, Ganna,
Abdou, Magdy O.,
Vlachopapadopoulou, Elpis,
Skorodok, Yulia,
Peterkova, Valentina,
Leff, Jonathan A.,
Beckert, Michael (2017) children with GHD.
Design: Randomized, open-label, active-controlled
study of three doses of weekly Trans
of preclinical and clinical
studies, the research work enabled to develop the
original solvent for poorly soluble
factors [1]. The protein tyrosine phosphatase
non-receptor type 22 (PTPN22) gene single
. According to epidemiological
studies, at least once during a lifetime this pathology is observed in 15
Kayumova, R.R.,
Sultanbaev, A.V.,
Ostakhov, S.S.,
Khursan, S.L.,
Abdullin, M.F.,
Gantsev, S.K.,
Sakaeva, D.D. (2017) THE «IN VIVO»
STUDY OF BLOOD 5-FLUOROURACIL CONTENT BY QUENCHING OF INTRINSIC PROTEIN FLUORESCENCE
Дьяконов, В.А.,
Джемилева, Л.У.,
Джемилев, У.М.,
D'yakonov, V.A.,
Dzhemileva, L.U.,
Dzhemilev, U.M. (2017) studies in this field have shown that topoisomerases I and II are one of the main molecular targets
Solovyev, A.V.,
Barashkov, N.A.,
Bady-Khoo, M.S.,
Zytsar, M.V.,
Posukh, O.L.,
Romanov, G.P.,
Rafailov, A.M.,
Sazonov, N.N.,
Alexeev, A.N.,
Dzhemileva, L.U.,
Khusnutdinova, E.K.,
Fedorova, S.A. (2017) -q12) associated with congenital
non-syndromic autosomal recessive deafness. This mutation